Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CRMD-001

Small molecule · developed by CorMedix Therapeutics

Phase 2 Most advanced trial (none active)
CRMD Developer
1 Registered trials

What is CRMD-001?

CRMD-001 is a formulation of deferiprone, given as immediate-release and extended-release tablets. It is studied in contrast-induced acute kidney injury in subjects undergoing angiography.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Renal & urology
Developer
CorMedix Therapeutics (CRMD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01146925 Phase 2 Contrast-Induced Acute Kidney Injury Completed CRMD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Contrast-Induced Acute Kidney Injury

More from CorMedix Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CRMD page.

Follow CRMD, the company behind CRMD-001

See CRMD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRMD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.